Evaluation of Pharmaceutical Care in Depressed Outpatients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-03-31

Study Completion Date

2012-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study examines whether pharmacotherapeutic follow-up improves outcomes of treatment of depressed outpatients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Role of Expectations in the Pharmacological Treatment of Depression - An Experimental Investigation

NCT03190772

Major Depressive Episode

COMPLETED NA

Fluoxetine Versus Fluoxetine Plus DU125530 in Major Depressive Disorder

NCT01119430

Major Depression

TERMINATED PHASE2

Early Improvement in Individual Symptoms and Response to Antidepressants in Patients With Major Depressive Disorder

NCT02934035

Major Depressive Disorder

UNKNOWN

Functional Change and Efficacy of Duloxetine in Patients With Co-Morbid Depression & Soft Tissue Discomfort Syndrome

NCT01035073

Major Depressive Disorder Soft Tissue Discomfort Syndrome Pain

COMPLETED PHASE4

Study of Desvenlafaxine in Treating Major Depressive Disorder.

NCT04364997

Major Depressive Disorder

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

control group

outpatients receiving usual care

Group Type NO_INTERVENTION

No interventions assigned to this group

intervention group

outpatients receiving pharmaceutical care or pharmacotherapeutic follow-up by 6 months

Group Type EXPERIMENTAL

pharmacotherapeutic follow-up

Intervention Type PROCEDURE

health education adjustment of dose improve compliance replacement of medication

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

pharmacotherapeutic follow-up

health education adjustment of dose improve compliance replacement of medication

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* women between 18 and 65 years, with diagnostic hypothesis of depression at the beginning of treatment or change in treatment unless 2 months (dosage or substance)

Exclusion Criteria

* record of dependence on psychoactive substances, diagnosed schizophrenia,
* low education (illiterate) or cognitive impairment evident that compromise the completion of research instruments

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No